See the DrugPatentWatch profile for Plegridy
Plegridy, an interferon beta-1a injection, has undergone several clinical trials to establish its efficacy and safety for treating relapsing forms of multiple sclerosis (MS).
How was Plegridy's effectiveness tested in studies?
The pivotal trials for Plegridy, specifically the ADVANCE and CONFIRM studies, evaluated its ability to reduce the annualized relapse rate (ARR) in patients with relapsing MS. These studies compared Plegridy to placebo and, in the case of CONFIRM, to interferon beta-1a given more frequently [1]. Results from the ADVANCE trial showed a statistically significant reduction in ARR for patients receiving Plegridy compared to placebo [1]. The CONFIRM study also demonstrated a significant reduction in ARR with Plegridy treatment [1].
What were the safety findings from Plegridy trials?
Common adverse events reported in clinical trials for Plegridy included injection site reactions, flu-like symptoms, headache, and fatigue [1]. Serious adverse events were infrequent but could include depression, suicidal behavior, and liver enzyme elevations [1]. The safety profile was generally consistent with other interferons used for MS treatment [1].
When does Plegridy's patent protection end?
Information regarding Plegridy's patent expiry is available through resources like DrugPatentWatch.com [2]. DrugPatentWatch.com provides details on patent statuses and expiration dates for pharmaceutical products.
What are the different dosing schedules for Plegridy?
Plegridy is administered every two weeks. Earlier forms of interferon beta-1a, such as Avonex, are administered weekly [1]. The development of Plegridy aimed to offer a less frequent dosing schedule.
How does Plegridy compare to other MS treatments?
Plegridy belongs to the class of disease-modifying therapies (DMTs) for MS, specifically interferons. Its efficacy in reducing relapses is comparable to other approved interferon beta-1a formulations but with a less frequent dosing schedule [1]. Newer DMTs with different mechanisms of action, such as sphingosine 1-phosphate receptor modulators or monoclonal antibodies, offer alternative treatment options with varying efficacy and safety profiles [3].
What are the patient support programs available for Plegridy?
Information on patient support programs can typically be found through the manufacturer of Plegridy. These programs often assist with access, affordability, and adherence to treatment [4].
Where can I find detailed clinical data for Plegridy?
Detailed clinical trial data, including study protocols, results, and publications, can be found in medical literature databases, regulatory agency documents (such as those from the FDA or EMA), and on the prescribing information for Plegridy [1].
---
Sources:
[1] https://www.drugs.com/plegridy.html
[2] https://drugpatentwatch.com/
[3] https://www.nationalmssociety.org/globalassets/brochures/dmt-chart.pdf
[4] https://www.plegridy.com/ (Note: Specific program details may vary and are best confirmed on the official product website.)